A number of companies are using the lessons and technologies of traditional genomics--the microarray chief among them--to delve into the more challenging world of functional genomics and proteomics.

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure ...

Bristol Myers Squibb's acquisition of Orbital Therapeutics includes OTX-201, a next-gen CAR T-cell therapy, and a proprietary ...

When immune cells strike, precision is everything. New research reveals how natural killer and T cells orchestrate the ...

There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and ...

Gene editing technology is being widely deployed to generate precise data about disease-causing gene mutations and networks, helping to identify optimal therapeutic targets. These approaches are ...

Cancer drug development is being stymied by a lack of two critical elements: novel gene targets and biomarkers for stratifying patients in clinical trials. MEDiC Life Sciences is addressing both gaps.

A research team has developed TropiCODB, a comprehensive multi-omics database designed to accelerate genetic improvement and precision biodesign in tropical crops.

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. Sudocetaxel zendusortide (TH1902), a novel ...

Algen has entered into a multi-target research collaboration with AstraZeneca to accelerate the identification of novel therapeutic targets in immunology.

Now that the human genome has been sequenced to a rough draft, the scientific community is looking down the road to what's next. Last month's announcement (see page 1) spotlights a nascent area of ...